BIO vs DMAC · rev $2.58B vs $157.4M cap
BIO (BIO) versus DiaMedica Therapeutics Inc (DMAC) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
DMAC does not have a complete income-statement cache yet.
BIO currently screens at market cap $0. DMAC currently screens at market cap $157.4M.
Not investment advice. Open the BIO and DMAC stock pages for the full models.
Not investment advice.